Please ensure Javascript is enabled for purposes of website accessibility

Why Tilray Led Canadian Cannabis Stocks Higher Today

By Howard Smith – Nov 3, 2021 at 4:21PM

Key Points

  • Philadelphia voters are trying to pressure the GOP legislature to support the full legalization of recreational cannabis.
  • Canadian companies have much to gain if the state-led movement ultimately gets federal support.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Election Day in the U.S. spurs hope for the future opening of a massive new market.

What happened

Canadian cannabis stocks surged on Wednesday, the day election results were announced in the United States. Shares of Tilray (TLRY -4.48%), OrganiGram Holdings (OGI -1.42%), and Hexo (HEXO) all jumped between 5% and 8.5% early in Wednesday's session as investors saw new results from U.S. voter referendums on marijuana legalization. The stocks pared some of those gains, but as of 3 p.m. EDT, each remained higher as shown below:

  • Tilray was up 4.5%.
  • OrganiGram was up 3.3%.
  • Hexo was up 7%.

So what

Voters in Pennsylvania's largest city overwhelmingly approved a ballot measure yesterday seeking to push Republican state legislators to fully legalize recreational marijuana. More than 70% of voters in Philadelphia supported a ballot question that is not legally binding, but was meant to show the state government voter support to legalize adult-use recreational marijuana.

marijuana flower buds on a weigh scale in a dispensary.

Image source: Getty Images.

With 19 states already having legalized weed, adding Pennsylvania would seemingly be another boost toward the trend that could ultimately lead to legalization at the federal level. That would bring a potential windfall for Canadian companies that have been posturing their businesses to take advantage of that outcome.

Now what

Canadian companies like Tilray have made no secret of their intentions to ultimately move into the U.S. market once federal legalization occurs. Tilray CEO Irwin Simon has laid out his company's plan to grow the business to one with an annual revenue base of $4 billion by the middle of calendar year 2024. For perspective, when the company announced its most recent quarterly financial update last month, it reported net revenue of $168 million for the three-month period ended Aug. 31. 

But a key part of Simon's plan is to leverage a U.S. consumer packaged goods platform that it has built through the acquisitions of SweetWater Brewing and Manitoba Harvest, a hemp, cannabidiol (CBD), and wellness brand. The company plans to sell cannabis through that infrastructure once marijuana is legal at the federal level. Simply put, Simon's vision won't come to fruition without that legalization development.

At the state level, legalization in Pennsylvania already has the support of Democratic Gov. Tom Wolf, and several cities including Philadelphia have approved local ordinances decriminalizing personal cannabis possession. But the Republican-led legislature hasn't joined the movement. Yesterday's vote was meant to push the state legislature to get behind legalization at the state level. 

For Canadian cannabis companies, that vote is just another in what they consider an inevitable wave toward federal approval. That still has a long way to go, however, but each step toward that goal in the U.S. brings potential for the Canadian companies like Tilray, OrganiGram, and Hexo to prosper in the future. That seems to be enough to have investors buying today. 

Howard Smith owns shares of Tilray, Inc. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends HEXO Corp. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.